Ibipinabant is a selective cannabinoid CB1 receptor antagonist previously investigated in clinical trials for conditions including obesity and related metabolic disorders. This category provides access… Read more
Ibipinabant is a selective cannabinoid CB1 receptor antagonist previously investigated in clinical trials for conditions including obesity and related metabolic disorders. This category provides access to high-quality reference standards essential for comprehensive impurity profiling and rigorous analytical testing of the drug substance. By utilizing Ibipinabant and its related impurities, such as the N-nitroso derivatives, researchers can ensure accurate method validation and consistency throughout pharmaceutical development. Additionally, the availability of stable isotope labelled compounds, including labelled rac-Ibipinabant, supports precise quantification and tracking in complex biological matrices via mass spectrometry. These reference materials are vital for quality control laboratories aiming to meet stringent regulatory requirements for substance characterization, providing the necessary tools to monitor degradation products and verify manufacturing process integrity during the lifecycle of the compound.